Keywords: مقاومت پلاتین; Nanoparticle; Combination therapy; Platinum resistance; Treatment synergy; Ovarian cancer;
مقالات ISI مقاومت پلاتین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مقاومت پلاتین; Ovarian cancer; Neoadjuvant chemotherapy; Primary debulking surgery; Platinum resistance;
Keywords: مقاومت پلاتین; Cisplatin; Carboplatin; Radio-sensitisation; Platinum-based chemotherapy; Platinum resistance; Platinum sensitivity
Keywords: مقاومت پلاتین; Non-small-cell lung cancer; Chemoradiation; Platinum resistance;
Keywords: مقاومت پلاتین; Obesity; High grade serous ovarian cancer; Inflammation; Cytokines; Platinum resistance
Activity profile of the cisplatin analogue PN149 in different tumor cell lines
Keywords: مقاومت پلاتین; CDDP; Cisplatin [Cis-Diammine-Dichloroplatinum(II)]; PN149; e-ammine-d-(3-amino-2,2,5,5-tetramethylpyrrolidine-1-oxyl; a; f-bis (butanoato); b; c-dichloroplatinum(IV); Platinum resistance; Cisplatin analogues; Platinum nitroxyl complexes; Gene expression
Original contributionHPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer
Keywords: مقاومت پلاتین; HPIP; Immunohistochemistry; Epithelial ovarian cancer; Platinum resistance;
ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients
Keywords: مقاومت پلاتین; NSCLC; non-small cell lung cancer; ABC; adenosine triphosphate-binding cassette; NCIC CTG; NCIC Clinical Trials Group; OS; overall survival; HWE; Hardy-Weinberg equilibrium; 95% CI; 95% confidence intervals; aHR; adjusted Hazard Ratios; Non-small cell l
A cyclometalated iridium(III) complex that induces apoptosis in cisplatin-resistant cancer cells
Keywords: مقاومت پلاتین; FRSBZNNXQRJRKT-UHFFFAOYSA-NIridium(III) complex; Platinum resistance; ROS; NF-κB; Apoptosis
Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth
Keywords: مقاومت پلاتین; BMP; BMPR1a; DMH1; Ovarian cancer; Platinum resistance
Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer
Keywords: مقاومت پلاتین; CTR1; Copper transporter; Non-small cell lung cancer; Platinum resistance; Drug transport; Drug resistance; Drug delivery; Transporter
TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction
Keywords: مقاومت پلاتین; Tumor necrosis factor α-induced protein 8; Epithelial ovarian cancer; Platinum resistance; Optimal cytoreduction;
Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma
Keywords: مقاومت پلاتین; Ovarian cancer; Platinum resistance; Neoadjuvant chemotherapy;
Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis
Keywords: مقاومت پلاتین; Epigenetics; Platinum resistance; Genomics; Ovarian Cancer; Apoptosis;
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance — A study of the OVCAD consortium
Keywords: مقاومت پلاتین; Primary ovarian cancer; Circulating tumor cells; Molecular marker; Platinum resistance; Prognostic marker
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
Keywords: مقاومت پلاتین; Perfosine; Docetaxel; Epithelial ovarian cancer; Platinum resistance; Taxane resistance; AKT
An environmentally-flexible measurement system for ammunition temperature detection in the powder chamber with high accuracy
Keywords: مقاومت پلاتین; Temperature measurement and conditioning; Platinum resistance; Software compensation
Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species
Keywords: مقاومت پلاتین; Costunolide; Apoptosis; ROS; Platinum resistance; Ovarian cancer
Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture
Keywords: مقاومت پلاتین; Ovarian cancer; Platinum resistance; Pathway analysis; Transforming growth factor beta
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer
Keywords: مقاومت پلاتین; Ovarian cancer; Epigenetics; Chemosensitization; Platinum resistance; DNMTI; HDAC inhibitor
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer — A phase II study
Keywords: مقاومت پلاتین; Whole-body hyperthermia; Ovarian cancer; Carboplatin; Platinum resistance
Can Surgical Debulking Reverse Platinum Resistance in Patients With Metastatic Epithelial Ovarian Cancer?
Keywords: مقاومت پلاتین; Platinum resistance; neoadjuvant chemotherapy; ovarian cancer;
Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients
Keywords: مقاومت پلاتین; MicroRNA; Ovarian cancer; Platinum resistance
Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance
Keywords: مقاومت پلاتین; DcR3; Apoptosis; Fas-ligand; Platinum resistance;
Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients
Keywords: مقاومت پلاتین; Ovarian cancer; NER polymorphisms; XP genes; XPA; XPC; XPD exon10; XPD exon23; XPG; Platinum sensitivity; Platinum resistance
Nucleotide excision repair pathway review I: Implications in ovarian cancer and platinum sensitivity
Keywords: مقاومت پلاتین; Nucleotide excision repair; DNA repair; Ovarian carcinoma; Platinum resistance; Polymorphisms
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum–taxane therapy: A phase II Austrian AGO study
Keywords: مقاومت پلاتین; Chemotherapy; PEG liposomal doxorubicin; Gemcitabine; Platinum resistance; Ovarian cancer